cardiology

MIT-Koch-Institute Madness
In the Lab

MIT’s Koch Institute wins STAT Madness with technology to see tiny ovarian tumors

By Elizabeth Cooney

Anatomical heart
Health

New drug from Merck, Bayer reduces hospitalizations for heart failure patients

By Matthew Herper

apple watches
Health Tech

The coronavirus is imperiling drug studies. A virtual study of the Apple Watch could be positioned to thrive

By Rebecca Robbins

Health

Her son died. Two decades later, she met the medical student who got his heart

By Karen Weintraub

Bayer Aspirin bottle
Pharma

Heart association admits ‘misstep’ in its drug-store aspirin displays with Bayer

By Phil Galewitz — Kaiser Health News

FDA through the window
Health Tech

AI has arrived in medical imaging. Now the FDA needs to monitor its impact on patients

By Casey Ross

Clogged Artery
Biotech

After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

By Matthew Herper

Balloon heart
Health

How the psychology of a $4.99 price tag might influence who undergoes heart surgery

By Eric Boodman

echocardiograms
Health

FDA approves AI-based software that helps doctors take ultrasound pictures of the heart

By Matthew Herper

Electrocardiogram readout
Pharmalot

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

By Ed Silverman

Open Heart Surgery
Health

‘Donation after cardiac death’: New heart transplant method being tested for the first time in the U.S.

By Shraddha Chakradhar

Regeneron HQ
Biotech

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

By Adam Feuerstein

AstraZeneca signage
Biotech

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

By Matthew Herper

Zachi Attai
Health Tech

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help real patients?

By Casey Ross

Vascepa pill handout
Biotech

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

By Matthew Herper

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Vascepa pill handout
Biotech

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

By Chris Morrison

non-emergency angioplasty
Health

Big study casts doubt on need for many heart procedures

By Associated Press

Apple watch with red band
Health

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

By Rebecca Robbins

Vascepa pill handout
Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Vascepa pill handout
Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Lipitor tablets
Health

Cholesterol levels dropping in U.S., but many still need care

By Associated Press

Heart graphic
Biotech

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

By Adam Feuerstein

Vascepa pill handout
Biotech

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

By Matthew Herper

Vioxx photo illo
Pharma

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

By Damian Garde

Heart ultrasound GIF
Health

An AI startup, led by 23andMe veteran Andy Page, tries to take better pictures of the heart

By Matthew Herper

Pharmalot

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

By Ed Silverman

FDA campus
Pharmalot

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

By Ed Silverman

Sept 11 Firefighters Health
Health

Some 9/11 firefighters may have higher heart risks now

By Associated Press

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy